{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:21Z","timestamp":1790009061681,"version":"4.0.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute\/National Institutes of Health","award":["R01CA138688"],"award-info":[{"award-number":["R01CA138688"]}]},{"name":"National Cancer Institute\/National Institutes of Health","award":["1RC1CA146299"],"award-info":[{"award-number":["1RC1CA146299"]}]},{"name":"National Cancer Institute\/National Institutes of Health","award":["P50CA136411"],"award-info":[{"award-number":["P50CA136411"]}]},{"name":"National Cancer Institute\/National Institutes of Health","award":["P50CA142509"],"award-info":[{"award-number":["P50CA142509"]}]},{"name":"MD Anderson's Cancer Center","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.bbcan.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T03:49:01Z","timestamp":1445572141000},"page":"58-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies"],"prefix":"10.1016","volume":"1865","author":[{"given":"Yi","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jeffrey Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2015.09.002_bb0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0010","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0015","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2","volume":"105","author":"Lazar-Molnar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0075","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/MCB.00319-13","article-title":"PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2","volume":"33","author":"Patsoukis","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084185","article-title":"B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade","volume":"8","author":"Nicholas","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.4049\/jimmunol.1101990","article-title":"Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens","volume":"187","author":"Haas","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0130","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.20121416","article-title":"PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis","volume":"210","author":"Zinselmeyer","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/cr.2008.80","article-title":"A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1","volume":"18","author":"Sheng","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0155","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0160","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/eji.200635978","article-title":"Contribution of the PD-1 ligands\/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation","volume":"36","author":"Kuipers","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0165","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2249.2005.02992.x","article-title":"Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12","volume":"143","author":"Van Keulen","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI16015","article-title":"Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis","volume":"111","author":"Dong","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0175","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0180","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1172\/JCI36604","article-title":"PD-L1 negatively regulates CD4+ CD25+ Foxp3+ tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV","volume":"119","author":"Franceschini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0185","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells","volume":"194","author":"Park","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0195","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2496","article-title":"The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood","volume":"14","author":"Sage","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.1217718","article-title":"The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut","volume":"336","author":"Kawamoto","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0205","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/vim.2011.0096","article-title":"PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection","volume":"25","author":"Norris","year":"2012","journal-title":"Viral Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0215","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0220","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4049\/jimmunol.1403143","article-title":"Imaging of cell-cell communication in a vertical orientation reveals high-resolution structure of immunological synapse and novel PD-1 dynamics","volume":"195","author":"Jang","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0225","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0230","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0235","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.immuni.2013.11.017","article-title":"Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues","volume":"40","author":"Honda","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0240","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0245","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0250","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0255","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/PAS.0b013e318165b0d6","article-title":"PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Nam-Cha","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0260","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0265","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","article-title":"Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines","volume":"56","author":"Chen","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0275","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"S, High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0280","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.201040979","article-title":"PD-L1 expression on tolerogenic APCs is controlled by STAT-3","volume":"41","author":"Wolfle","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0285","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0290","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0295","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0305","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0310","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0315","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0320","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0325","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0330","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0340","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0345","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emu-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0350","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0355","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0360","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0365","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in sezary syndrome and mycosis fungoides","volume":"148","author":"Cetinozman","year":"2012","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0370","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/PAS.0b013e318230df87","article-title":"Expression of programmed death-1 in primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma","volume":"36","author":"Cetinozman","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/DAD.0b013e31825b26d1","article-title":"CD4\/CD8 double negative mycosis fungoides with PD-1 (CD279) expression\u2013a disease of follicular helper T-cells?","volume":"34","author":"Kempf","year":"2012","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0380","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","article-title":"B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0385","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","article-title":"Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma","volume":"94","author":"Paydas","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0390","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/icb.2010.121","article-title":"PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma","volume":"89","author":"Ni","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0395","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0400","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0410","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"L.Y.M.s. investigators, bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","volume":"12","author":"Coiffier","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0415","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0420","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","article-title":"Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies","volume":"124","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0425","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0430","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0435","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","article-title":"Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab","volume":"54","author":"Johnston","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0440","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","volume":"35","author":"Postow","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0450","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.cji.0000177999.95831.7b","article-title":"Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells","volume":"28","author":"Hinrichs","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0455","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0460","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0465","first-page":"1","article-title":"The heterogeneity of the kinetics of response to Ipilimumab in metastatic melanoma: patient cases","volume":"8","author":"Saenger","year":"2008","journal-title":"Cancer Immun."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0470","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0475","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0092-8674(05)80055-8","article-title":"Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7\/BB1 in interleukin-2 production and immunotherapy","volume":"71","author":"Schwartz","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0480","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504030","article-title":"combined nivolumab and ipilimumab or monotherapy in untreated melanoma","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0485","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0490","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0495","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0500","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27297","article-title":"Trial watch: immunostimulatory monoclonal antibodies in cancer therapy","volume":"3","author":"Aranda","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0505","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-12-2065","article-title":"Agonist antibodies to TNFR molecules that costimulate T and NK cells","volume":"19","author":"Melero","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0510","first-page":"129","article-title":"Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor","volume":"35","author":"Shindo","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0515","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4049\/jimmunol.1401644","article-title":"OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence","volume":"194","author":"Buchan","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0520","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Kohrt","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0525","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0530","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.177.1.130","article-title":"Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO","volume":"177","author":"Belladonna","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0535","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0540","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0545","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0550","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb0555","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2010-04-283119","article-title":"PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells","volume":"117","author":"Koestner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb0560","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood.V124.21.3964.3964","article-title":"A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation","volume":"124","author":"Davids","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2015.09.002_bb9113","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/annonc\/mdv019","article-title":"Genetic lesions in diffuse large B-cell lymphomas","volume":"26","author":"Testoni","year":"2015","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb9114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/path.4522","article-title":"Recurrent genomic rearrangements in rimary testicular lymphoma","volume":"236","author":"Twa","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2015.09.002_bb9115","series-title":"Neoplastic Hematopathology","first-page":"502","article-title":"Diffuse large B-cell lymphoma","author":"Young","year":"2014"},{"key":"10.1016\/j.bbcan.2015.09.002_bb9116","article-title":"Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium","author":"Deng","year":"2015","journal-title":"Leukemia"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X15000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X15000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T03:19:58Z","timestamp":1599707998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X15000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0304419X15000694"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2015.09.002","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}